Chinese biotechs push healthcare IPOs past 2020 total in Q3'21afinklerWed, 11/24/2021 - 08:15Printable versionSend by emailPDF version
Michael Cole, healthcare industry leader for Alvarez & Marsal's Global Transaction Advisory Group, pointed out that this year saw the highest third-quarter IPO volume in the last 20 years despite the drop from the second quarter of 2021 in S&P Global Market Intelligence.
"There's just a lot of demand for companies that can do a lot of things, and in healthcare that's responding to the need for innovation, namely, in the life sciences and biotech side on the heels of the pandemic and the increased need for digitization," Cole said.